5-Amino-1MQ is an emerging small-molecule compound that has drawn significant attention from metabolic researchers for its ability to inhibit nicotinamide N-methyltransferase (NNMT) — an enzyme increasingly recognized as a key regulator of fat cell biology, energy expenditure, and NAD+ metabolism. As interest in metabolic peptide research continues to accelerate in 2026, 5-Amino-1MQ occupies a unique position: it is not a peptide in the classical sense, but a methylquinolinium derivative that modulates cellular metabolism at the enzymatic level in ways that parallel and complement peptide-based interventions.
Preclinical research into 5-Amino-1MQ has primarily explored its role in adipocyte metabolism, its capacity to reduce fat cell size, and its interactions with the broader NAD+/SAM (S-adenosylmethionine) axis. For researchers studying obesity biology, energy metabolism, or cellular epigenetics, understanding how 5-Amino-1MQ functions at the mechanistic level is increasingly relevant to designing well-rounded experimental frameworks.
Research-only notice: This content is provided for educational discussion and laboratory research purposes only. No medical claims are made or implied. 5-Amino-1MQ is intended exclusively for use in licensed research settings and is not approved for human consumption or therapeutic application.
5-Amino-1MQ - 50mg — Research-Grade Reference Material 5-Amino-1MQ - 50mg is supplied as a lyophilized powder for in-vitro laboratory research use only. SourcePeptides supplies this material strictly as a laboratory reference standard.…
View Research Data
Pfizer Hospira Bacteriostatic Water – 30 mL
$45.00$33.75 with 1st order
NAD - 500MG
$70.00$52.50 with 1st order
DSIP - 10MG
$70.00$52.50 with 1st order
IGF-1 LR3 1MG
$65.00$48.75 with 1st order
Frequently Asked Questions
What is 5-Amino-1MQ?
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule NNMT inhibitor studied in preclinical models for its effects on fat cell metabolism, energy expenditure, and NAD+ pathway regulation. It is not a traditional peptide but is often grouped with metabolic research compounds due to its overlapping mechanisms with peptides like MOTS-C and AOD-9604.
What does NNMT do, and why does inhibiting it matter for fat metabolism research?
Nicotinamide N-methyltransferase (NNMT) is an enzyme found in high concentrations in adipose tissue. Research suggests NNMT consumes SAM (S-adenosylmethionine) and converts it to methylnicotinamide, effectively reducing the availability of methyl groups for epigenetic regulation and NAD+ precursor recycling. Studies have shown that elevated NNMT activity correlates with obesity and metabolic dysfunction, making its inhibition a research target for restoring metabolic efficiency in fat cells.
How does 5-Amino-1MQ affect adipocytes in preclinical studies?
In preclinical research, 5-Amino-1MQ has been shown to reduce lipid accumulation in adipocytes, decrease fat cell size, and upregulate genes associated with energy expenditure. Studies in rodent models have reported reductions in body weight and fat mass without corresponding reductions in lean muscle mass, which has made it a subject of ongoing metabolic investigation.
How does 5-Amino-1MQ relate to NAD+ metabolism?
By inhibiting NNMT, 5-Amino-1MQ research suggests it may preserve SAM availability and support NAD+ precursor recycling. This mechanism links it conceptually to the broader NAD+ research landscape, where compounds like NMN and NR are also studied for their metabolic and mitochondrial effects. Researchers sometimes study 5-Amino-1MQ alongside NAD+ compounds to explore complementary pathways.
Is 5-Amino-1MQ the same as a weight loss peptide?
5-Amino-1MQ is technically a small molecule rather than a peptide, though it is often discussed alongside research peptides due to similar metabolic research contexts. It differs mechanistically from GLP-1-class compounds or AOD-9604, operating on NNMT inhibition rather than receptor agonism or growth hormone fragment activity.
What research models have been used to study 5-Amino-1MQ?
The primary research models to date have been in vitro cell culture studies using murine and human adipocytes, as well as high-fat diet rodent models. These preclinical studies have examined changes in fat mass, gene expression patterns, and metabolic rate markers. Human clinical data remains limited as of 2026.
Can 5-Amino-1MQ be stacked with other metabolic research compounds?
Researchers have conceptually explored 5-Amino-1MQ in combination with compounds affecting the NAD+ axis, GLP-class peptides, and mitochondrial modulators. However, combination research remains in early stages and most published findings come from single-compound preclinical models.
Understanding NNMT: The Enzyme at the Center of 5-Amino-1MQ Research
To understand why 5-Amino-1MQ has attracted research interest, it is essential to first understand nicotinamide N-methyltransferase (NNMT). NNMT is a cytosolic enzyme that catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM) to nicotinamide, producing S-adenosylhomocysteine (SAH) and 1-methylnicotinamide (MNA). While this process appears metabolically minor in isolation, research has revealed that NNMT activity has outsized effects on cellular metabolism — particularly in white adipose tissue.
5-Amino-1MQ - 50mg — Research-Grade Reference Material 5-Amino-1MQ - 50mg is supplied as a lyophilized powder for in-vitro laboratory research use only. SourcePeptides supplies this material strictly as a laboratory reference standard.…
View Research Data
Pfizer Hospira Bacteriostatic Water – 30 mL
$45.00$33.75 with 1st order
NAD - 500MG
$70.00$52.50 with 1st order
DSIP - 10MG
$70.00$52.50 with 1st order
IGF-1 LR3 1MG
$65.00$48.75 with 1st order
Studies have found that NNMT expression is significantly elevated in the adipose tissue of obese individuals and in high-fat diet rodent models. Because NNMT consumes SAM — the cell’s primary methyl donor — elevated NNMT activity effectively depletes methyl groups that would otherwise be used for DNA and histone methylation. This epigenetic disruption has been hypothesized to suppress metabolic gene expression in fat cells, creating a self-perpetuating cycle of reduced energy expenditure and increased lipid storage.
Additionally, the nicotinamide consumed by NNMT is a direct precursor to NAD+. When NNMT activity is high, less nicotinamide is available for NAD+ biosynthesis via the salvage pathway. This connects NNMT overactivity to the broader theme of NAD+ depletion in metabolic dysfunction — a topic explored extensively in NAD+ 500MG nasal spray research and its relationship to mitochondrial efficiency.
5-Amino-1MQ: Mechanism of NNMT Inhibition
5-Amino-1MQ is a cell-permeable, small-molecule inhibitor designed to competitively block NNMT’s active site. Its structure — a methylquinolinium derivative — allows it to penetrate adipocyte cell membranes and interfere with NNMT’s catalytic function without requiring the complex receptor-binding processes associated with peptide hormones.
Mechanistically, preclinical research suggests that 5-Amino-1MQ inhibition of NNMT produces several downstream effects in fat cells:
- SAM preservation: By reducing NNMT activity, more SAM is available for methylation reactions, potentially restoring epigenetic regulation of metabolic genes in adipocytes.
- NAD+ precursor availability: With less nicotinamide being diverted into the NNMT pathway, more is available for conversion to NAD+ via NAMPT (nicotinamide phosphoribosyltransferase), the rate-limiting enzyme in the NAD+ salvage pathway.
- Gene expression shifts: Studies in adipocyte models have observed upregulation of genes associated with thermogenesis and mitochondrial biogenesis following NNMT inhibition, suggesting a shift toward more metabolically active fat cell phenotypes.
- Reduced lipid accumulation: Multiple in vitro studies have reported decreased triglyceride accumulation in adipocytes treated with 5-Amino-1MQ compared to controls.
This mechanistic profile distinguishes 5-Amino-1MQ from peptide-based metabolic tools. Where compounds like SLU-PP-322 and AOD-9604 operate through nuclear receptor agonism or growth hormone fragment activity, 5-Amino-1MQ works at the epigenetic and metabolite availability level — offering a distinct angle for researchers building multi-mechanism metabolic study frameworks.
5-Amino-1MQ 50MG for research →
Key Preclinical Findings: What Studies Have Shown
Rodent High-Fat Diet Models
The most cited preclinical data on 5-Amino-1MQ comes from high-fat diet (HFD) rodent models. In a study published in Cell Chemical Biology (Kannt et al. and related groups), NNMT inhibition using small-molecule inhibitors including 5-Amino-1MQ analogs was associated with significant reductions in body weight gain, adipose tissue expansion, and circulating triglycerides compared to untreated controls on the same diet.
Importantly, these studies reported that the reductions in fat mass occurred without meaningful reductions in lean body mass — a finding that distinguishes this mechanism from broad caloric restriction models, where both fat and muscle are typically reduced. This specificity has made NNMT inhibition a particularly interesting research target for researchers investigating fat-selective metabolic modulation.
Adipocyte In Vitro Research
In vitro studies using differentiated adipocytes have provided mechanistic confirmation for the in vivo findings. When adipocytes are treated with 5-Amino-1MQ, research has observed:
- Decreased lipid droplet size and reduced intracellular triglyceride content
- Elevated expression of PGC-1α, a master regulator of mitochondrial biogenesis
- Upregulation of UCP1 and related thermogenic gene markers
- Increased NAMPT activity and corresponding NAD+ levels within treated cells
These findings suggest that NNMT inhibition does not simply block fat storage passively but may actively reprogram fat cells toward more energetically active states — a concept researchers have described as “browning” of white adipose tissue, though this terminology remains under scientific scrutiny.
Comparison to Other Metabolic Research Compounds
Researchers studying the metabolic research landscape in 2026 often compare 5-Amino-1MQ to other compounds in preclinical studies. The table below illustrates key mechanistic distinctions for research reference:
| Feature | 5-Amino-1MQ | AOD-9604 | SLU-PP-322 |
|---|---|---|---|
| Compound class | Small molecule | Peptide fragment | Small molecule |
| Primary mechanism | NNMT inhibition | GH fragment / β3-AR | ERRα/γ agonism |
| Target tissue | White adipose tissue | Adipose tissue | Skeletal muscle / liver |
| NAD+ pathway involvement | Yes (indirect, via SAM/NAMPT) | No | Yes (via mitochondrial biogenesis) |
| Lean mass preservation (preclinical) | Reported in HFD models | Reported in some models | Reported in exercise mimetic studies |
| Human trial data (as of 2026) | Minimal | Limited | Minimal |
For researchers interested in the broader GLP-1 and incretin-based research space, GLP-1 vs GLP-2 vs GLP-3 weight loss research covers receptor-mediated metabolic mechanisms that operate through entirely different pathways than NNMT inhibition, making them potentially complementary study subjects.
5-Amino-1MQ and the NAD+ Connection
One of the more nuanced aspects of 5-Amino-1MQ research is its intersection with NAD+ biology. Because NNMT directly competes with the NAD+ salvage pathway for nicotinamide substrate, elevated NNMT activity effectively reduces cellular NAD+ production. Researchers studying metabolic aging, mitochondrial efficiency, and cellular energy have noted that NNMT overactivity may represent an underappreciated contributor to the age-associated decline in NAD+ levels.
This has led some research teams to explore whether 5-Amino-1MQ, by preserving nicotinamide availability for NAD+ synthesis, could function as an indirect NAD+ booster at the cellular level — complementing rather than replacing direct NAD+ precursor supplementation strategies studied in contexts like MOTS-C vs NAD+ mitochondrial research.
The SAM axis is equally relevant. SAM availability regulates histone and DNA methylation patterns across the genome, and research into epigenetic metabolic reprogramming increasingly points to SAM depletion as a driver of metabolic gene silencing in obese adipose tissue. 5-Amino-1MQ’s capacity to preserve SAM by reducing NNMT-mediated consumption makes it an interesting tool for researchers studying the epigenetic dimensions of obesity biology.
NAD+ 500MG Nasal Spray for research →
Research Context: Where 5-Amino-1MQ Fits in 2026
The broader metabolic research environment in 2026 has seen intensifying interest in multi-pathway approaches to fat metabolism and energy regulation. GLP-class peptides have dominated headlines, but researchers are increasingly looking beyond receptor agonism to understand how cellular enzyme activity, epigenetic regulation, and metabolite availability shape metabolic phenotypes.
5-Amino-1MQ fits naturally into research programs that:
- Investigate the role of NNMT overexpression in obesity and insulin resistance models
- Study SAM-mediated epigenetic regulation of adipose tissue gene expression
- Explore NAD+ salvage pathway dynamics in metabolically stressed cells
- Compare NNMT inhibition to direct NAD+ precursor strategies in restoring mitochondrial function
- Design combination frameworks alongside GLP-class or mitochondrial peptides for multi-mechanism metabolic studies
Researchers exploring fat-selective metabolic modulation may also find value in reviewing how AOD-9604 research has approached similar questions through a growth hormone fragment mechanism — the SLU-PP-322 vs AOD-9604 comparison guide offers a useful side-by-side perspective on mechanistic diversity in this space.
Research Design Considerations for 5-Amino-1MQ Studies
For researchers incorporating 5-Amino-1MQ into laboratory protocols, several design considerations are worth noting based on the existing preclinical literature:
- Cell-permeable formulation: 5-Amino-1MQ’s small-molecule structure allows it to cross cell membranes without requiring specialized delivery carriers, simplifying in vitro experimental design compared to some peptide-based compounds.
- NNMT activity assays: Measuring NNMT enzymatic activity and downstream SAM/SAH ratios provides direct mechanistic confirmation in research models rather than relying solely on phenotypic fat mass readouts.
- NAD+ level tracking: Because the NAD+ salvage pathway is mechanistically linked to NNMT inhibition, tracking intracellular NAD+ concentrations in treated vs. control cells provides important mechanistic context.
- Gene expression panels: Studies have used qPCR to track PGC-1α, UCP1, PRDM16, and related thermogenic/mitochondrial markers as secondary endpoints in 5-Amino-1MQ experiments.
- Diet-matched controls: In animal model designs, strict diet matching between treatment and control groups is critical given NNMT’s sensitivity to nutritional state and dietary fat content.
Where These Fit in Your Research Library
Researchers building a comprehensive metabolic study framework may want to explore related compounds:
MOTS-C 10MG Nasal Spray for research →
GLP-1 (S) 10MG Nasal Spray for research →
Browse the full research peptide catalog →
Final Takeaway: 5-Amino-1MQ as a Metabolic Research Tool in 2026
5-Amino-1MQ represents one of the more mechanistically distinct tools available for preclinical metabolic research. By targeting NNMT — an enzyme that sits at the intersection of SAM metabolism, NAD+ biosynthesis, and epigenetic regulation in adipose tissue — it offers researchers a non-peptide lever for studying fat cell biology at a level that receptor-agonist compounds do not reach.
Preclinical studies have consistently shown reductions in adipocyte lipid accumulation, favorable gene expression shifts toward thermogenesis, and lean mass preservation in HFD rodent models. These findings position 5-Amino-1MQ as a valuable tool for researchers exploring the enzymatic and epigenetic drivers of metabolic dysfunction — particularly those seeking to complement receptor-level interventions with upstream metabolic pathway modulation.
As with all research compounds discussed in this guide, 5-Amino-1MQ is intended strictly for laboratory research use. Human clinical data remains limited, and all research should be conducted in accordance with institutional protocols and applicable regulations.
Sources & Further Reading
- Kannt A et al. — “A small molecule inhibitor of Nicotinamide N-methyltransferase for the treatment of metabolic disorders” — Scientific Reports (2018)
- Kraus D et al. — “Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity” — Nature (2014)
- Hong S et al. — “Nicotinamide N-methyltransferase regulates hepatic nutrient metabolism through Sirt1 protein stabilization” — Nature Chemical Biology (2015)
- PubMed search: 5-Amino-1MQ NNMT inhibitor research
- PubMed search: NNMT adipose tissue obesity studies
